Business Wire

New Bipolar Disorder Study Shows that a Ketogenic Diet Leads to Mental and Physical Health Benefits

Share

Baszucki Group today announced a new pilot study on a ketogenic diet in bipolar disorder. “For the first time in years, I felt like my brain was finally running on the right fuel,” said one of the study participants. Published today in BJPsych Open, the study is the first to use neuroimaging to demonstrate that a ketogenic diet may improve brain metabolism in individuals with a bipolar disorder diagnosis. With over 100 years of evidence of efficacy in epilepsy, a ketogenic diet is now being studied around the world for a variety of psychiatric and neurological conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211683582/en/

The first-of-its-kind European study, supported by Baszucki Group, used advanced brain imaging techniques, including magnetic resonance spectroscopy (MRS), to measure changes in brain metabolism. The imaging revealed reductions in excitatory neurotransmitters typically elevated in bipolar disorder, suggesting a potential mechanism behind a ketogenic diet's effectiveness. The study also showed that ketone levels correlated with symptom improvement in a subset of individuals who reported daily ratings. This pilot trial points to an important new direction for research and offers hope for innovative treatment options for individuals living with this serious mental illness.

Co-led by University of Edinburgh scientists Iain Campbell, PhD, a Baszucki Metabolic Psychiatry Research Fellow, Daniel Smith, MD, FRCPsych, Chair of Psychiatry, and Harry Campbell, MD, FRSE, FMedSci, the research team enrolled 27 participants with bipolar disorder into a 6-8 week pilot trial of a ketogenic diet. Twenty participants completed the study, demonstrating that the intervention was safe and tolerable in this population. Most reached and maintained ketosis, with 91% of readings positive for blood ketones. Among participants who provided reliable daily ketone and mental health data assessments, increased ketone level was correlated with improvements in mood, energy, impulsivity, and anxiety, with some describing the intervention as life-changing.

“A ketogenic diet gave me a lifeline, restoring my energy and sense of hope,” said a study participant. “I felt like I was finally healing my mind, not just managing my bipolar symptoms. It opened me up to new possibilities and a brighter future.”

“Using a ketogenic diet is like giving my mind a warm bath,” said another participant. “The edginess is gone. I feel calmer, clearer, and my brain is working again.”

Markers of metabolic function also improved. Nineteen of 20 participants lost an average of 9.3 pounds (4.2kg) and saw improvements in body mass index (BMI) and blood pressure. These findings suggest that a ketogenic diet may help mitigate common metabolic health risks associated with bipolar disorder and its pharmacological treatments, which can lead to shortened life spans.

“We observed markers of reduced excitotoxicity in two key brain areas: the anterior cingulate cortex and posterior cingulate cortex—both implicated in bipolar disorder. We also observed effects on a marker which has been associated with Lithium and insulin signaling in the posterior cingulate cortex ” said Dr. Iain Campbell, who also lives with the disorder and follows a ketogenic diet to alleviate his symptoms. “These results add to a small but growing body of evidence suggesting that a ketogenic diet may be an effective adjunctive metabolic intervention for bipolar disorder. There is an urgent need for larger replication studies and carefully designed randomized clinical trials to build on these findings."

These changes align with the metabolic overdrive hypothesis, a theory Drs. Campbell have proposed, which posits that energy dysregulation is central to the mechanism of bipolar disorder and that addressing this dysregulation may be key to the success of ketogenic diet therapy.

A New Frontier in Mental Health

This pilot study paved the way for a broader initiative at the University of Edinburgh, made possible by a competitive research grant from the UKRI Medical Research Council that established the first European Metabolic Psychiatry Hub. The hub, to which Baszucki Group also contributed funding, is a collaboration of over 100 scientists dedicated to accelerating research into the connections between metabolism and mental health. Its focus is to explore the potential of ketogenic therapy and other metabolic interventions for treating severe mental illnesses.

This study is the second recently published pilot trial to demonstrate the safety and potential efficacy of ketogenic therapy in improving both metabolic and mental health markers in serious mental illness. The first trial, also funded by Baszucki Group, was conducted at Stanford University and also suggested that systemic metabolic changes from a ketogenic diet may help stabilize the brain in serious mental illness.

“This trial is another important step forward in establishing ketogenic therapy as a standard treatment for serious mental illness,” said Jan Ellison Baszucki, co-founder and President of Baszucki Group. “We’re proud to have supported this research and remain hopeful that ongoing studies will continue to advance our understanding of the metabolic intervention that saved our son’s life.”

As awareness grows about the deep connection between metabolic function and brain health, this study advances the global scientific movement toward neurometabolic approaches to understanding and treating mental illness.

About Baszucki Group

Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211683582/en/

Contacts

Colby Zintl colby@baszuckigroup.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 12:13:00 EEST | Press release

SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag

Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release

The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China

The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release

The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye